SGTX News and Press, Sigilon Therapeutics Inc. From 11/10/22

Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q3 GAAP EPS of -$0.27 beats by $0.15 . Revenue of $4.25M (+117.9% Y/Y) beats by $1.75M . For further details see: Sigilon Therapeutics GAAP EPS of -$0.27 beats by $0.15, revenue of $4.25M beats by $1.75...

Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the ...

Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q2 GAAP EPS of -$0.44. Collaboration Revenue of $2.88M (+6.7% Y/Y). Cash, cash equivalents and marketable securities were $88.2 million as of June 30, 2022 compared to $123.4 million as of December 31, 2021. ...

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the second quart...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Sigilon Therapeutics press release (NASDAQ:SGTX): Q1 GAAP EPS of -$0.43. Collaboration revenue of $3.17M. For further details see: Sigilon Therapeutics GAAP EPS of -$0.43, revenue of $3.17M

On track to announce results from preclinical studies of SIG-005 in second half of 2022 Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company th...

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executi...

The following slide deck was published by Sigilon Therapeutics, Inc. in conjunction with this event. For further details see: Sigilon Therapeutics (SGTX) Investor Presentation - Slideshow

Sigilon Therapeutics press release (NASDAQ:SGTX):Q4 GAAP EPS of -$0.55. Q4 Revenue of $1.99M (-46.9% Y/Y). For further details see: Sigilon Therapeutics GAAP EPS of -$0.55, revenue of $1.99M